Marion Wealth Management Buys Shares of 2,262 Boston Scientific Co. (NYSE:BSX)

Marion Wealth Management purchased a new position in shares of Boston Scientific Co. (NYSE:BSX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,262 shares of the medical equipment provider’s stock, valued at approximately $202,000.

Other hedge funds have also recently modified their holdings of the company. Courier Capital LLC raised its position in Boston Scientific by 108.7% during the 4th quarter. Courier Capital LLC now owns 22,384 shares of the medical equipment provider’s stock worth $1,999,000 after buying an additional 11,661 shares during the last quarter. Miracle Mile Advisors LLC lifted its position in Boston Scientific by 4.7% in the fourth quarter. Miracle Mile Advisors LLC now owns 5,498 shares of the medical equipment provider’s stock valued at $491,000 after purchasing an additional 246 shares during the period. Claro Advisors LLC purchased a new stake in Boston Scientific in the 4th quarter valued at approximately $244,000. Moody National Bank Trust Division acquired a new position in Boston Scientific during the 4th quarter worth approximately $249,000. Finally, Wedmont Private Capital raised its stake in shares of Boston Scientific by 8.0% during the 4th quarter. Wedmont Private Capital now owns 20,236 shares of the medical equipment provider’s stock worth $1,920,000 after buying an additional 1,506 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on BSX shares. JPMorgan Chase & Co. upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Mizuho upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Morgan Stanley boosted their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. BTIG Research increased their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, TD Cowen boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $97.26.

Boston Scientific Trading Down 0.1 %

Shares of NYSE BSX traded down $0.10 on Monday, reaching $94.78. 4,213,782 shares of the company traded hands, compared to its average volume of 5,358,167. The stock has a market capitalization of $139.69 billion, a PE ratio of 78.33, a P/E/G ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a fifty-two week low of $59.61 and a fifty-two week high of $97.13. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a 50 day moving average of $89.96 and a 200 day moving average of $83.89.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.50 earnings per share. On average, equities research analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 4,119 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,989 shares of company stock valued at $2,702,261. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.